{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:39:42Z","timestamp":1757623182629,"version":"3.44.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Neurological Disorders and Stroke\/National Institute of Health","award":["NS047198"],"award-info":[{"award-number":["NS047198"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s11064-025-04508-6","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T10:16:05Z","timestamp":1755080165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biological Characterization of the Anti-ferroptotic Properties of a Novel Anti-Parkinsonian Iron (II) Selective Dopamine Agonist, D-583"],"prefix":"10.1007","volume":"50","author":[{"given":"Vibha","family":"Deshpande","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Schick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purba","family":"Mazumder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aloke K.","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"4508_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1212\/WNL.58.2.179","volume":"58","author":"MM Mouradian","year":"2002","unstructured":"Mouradian MM (2002) Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 58:179\u2013185","journal-title":"Neurology"},{"key":"4508_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev.neuro.28.061604.135718","volume":"28","author":"DJ Moore","year":"2005","unstructured":"Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of parkinson\u2019s disease. Annu Rev Neurosci 28:57\u201387","journal-title":"Annu Rev Neurosci"},{"key":"4508_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00005072-199603000-00001","volume":"55","author":"LS Forno","year":"1996","unstructured":"Forno LS (1996) Neuropathology of parkinson\u2019s disease. J Neuropathol Exp Neurol 55:259\u2013272","journal-title":"J Neuropathol Exp Neurol"},{"key":"4508_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in lewy bodies. Nature 388:839\u2013840","journal-title":"Nature"},{"key":"4508_CR5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/00005072-199111000-00006","volume":"50","author":"W Paulus","year":"1991","unstructured":"Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of parkinson\u2019s disease. J Neuropathol Exp Neurol 50:743\u2013755","journal-title":"J Neuropathol Exp Neurol"},{"key":"4508_CR6","first-page":"657","volume":"2","author":"TB Sherer","year":"2001","unstructured":"Sherer TB, Betarbet R, Greenamyre JT (2001) Pathogenesis of parkinson\u2019s disease. Curr Opin Investig Drugs 2:657\u2013662","journal-title":"Curr Opin Investig Drugs"},{"key":"4508_CR7","volume-title":"Movement disorders. Neurologic principles and practice","author":"GF Wooten","year":"1997","unstructured":"Wooten GF (1997) Movement disorders. Neurologic principles and practice. McGraw-Hill, New York"},{"key":"4508_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1474-4422(03)00501-5","volume":"2","author":"DA Di Monte","year":"2003","unstructured":"Di Monte DA (2003) The environment and parkinson\u2019s disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2:531\u2013538","journal-title":"Lancet Neurol"},{"issue":"Suppl 3","key":"4508_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/ana.10483","volume":"53","author":"P Jenner","year":"2003","unstructured":"Jenner P (2003) Oxidative stress in parkinson\u2019s disease. Ann Neurol 53(Suppl 3):26\u201336","journal-title":"Ann Neurol"},{"issue":"Suppl 3","key":"4508_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1353-8020(09)70812-0","volume":"15","author":"MF Beal","year":"2009","unstructured":"Beal MF (2009) Therapeutic approaches to mitochondrial dysfunction in parkinson\u2019s disease. Parkinsonism Relat Disord 15(Suppl 3):189\u2013194","journal-title":"Parkinsonism Relat Disord"},{"key":"4508_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0162-0134(99)00238-X","volume":"79","author":"W Linert","year":"2000","unstructured":"Linert W, Jameson GN (2000) Redox reactions of neurotransmitters possibly involved in the progression of parkinson\u2019s disease. J Inorg Biochem 79:319\u2013326","journal-title":"J Inorg Biochem"},{"key":"4508_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/0925-4439(96)00020-8","volume":"1316","author":"W Linert","year":"1996","unstructured":"Linert W, Herlinger E, Jameson RF, Kienzl E, Jellinger K, Youdim MB (1996) Dopamine, 6-hydroxydopamine, iron, and dioxygen\u2013their mutual interactions and possible implication in the development of parkinson\u2019s disease. Biochim Biophys Acta 1316:160\u2013168","journal-title":"Biochim Biophys Acta"},{"key":"4508_CR13","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1038\/emboj.2012.170","volume":"31","author":"N Exner","year":"2012","unstructured":"Exner N, Lutz AK, Haass C, Winklhofer KF (2012) Mitochondrial dysfunction in parkinson\u2019s disease: molecular mechanisms and pathophysiological consequences. EMBO J 31:3038\u20133062","journal-title":"EMBO J"},{"key":"4508_CR14","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nature05292","volume":"443","author":"MT Lin","year":"2006","unstructured":"Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787\u2013795","journal-title":"Nature"},{"key":"4508_CR15","doi-asserted-by":"publisher","first-page":"A32","DOI":"10.1038\/399a032","volume":"399","author":"SB Dunnett","year":"1999","unstructured":"Dunnett SB, Bjorklund A (1999) Prospects for new restorative and neuroprotective treatments in parkinson\u2019s disease. Nature 399:A32\u201339 PMID 10392578","journal-title":"Nature"},{"key":"4508_CR16","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1087753","volume":"302","author":"TM Dawson","year":"2003","unstructured":"Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in parkinson\u2019s disease. Science 302:819\u2013822 PMID 14593166","journal-title":"Science"},{"key":"4508_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1471-4159.2001.00608.x","volume":"79","author":"D Berg","year":"2001","unstructured":"Berg D, Gerlach M, Youdim MB, Double KL, Zecca L, Riederer P, Becker G (2001) Brain iron pathways and their relevance to parkinson\u2019s disease. J Neurochem 79:225\u2013236","journal-title":"J Neurochem"},{"key":"4508_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/BF01244786","volume":"74","author":"E Sofic","year":"1988","unstructured":"Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MB (1988) Increased iron (III) and total iron content in post mortem substantia Nigra of parkinsonian brain. J Neural Transm 74:199\u2013205","journal-title":"J Neural Transm"},{"key":"4508_CR19","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1111\/j.1471-4159.1989.tb07264.x","volume":"52","author":"DT Dexter","year":"1989","unstructured":"Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in parkinson\u2019s disease. J Neurochem 52:1830\u20131836","journal-title":"J Neurochem"},{"key":"4508_CR20","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1212\/WNL.45.6.1138","volume":"45","author":"JM Gorell","year":"1995","unstructured":"Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA (1995) Increased iron-related MRI contrast in the substantia Nigra in parkinson\u2019s disease. Neurology 45:1138\u20131143","journal-title":"Neurology"},{"key":"4508_CR21","first-page":"273","volume":"60","author":"DT Dexter","year":"1993","unstructured":"Dexter DT, Sian J, Jenner P, Marsden CD (1993) Implications of alterations in trace element levels in brain in parkinson\u2019s disease and other neurological disorders affecting the basal ganglia. Adv Neurol 60:273\u2013281","journal-title":"Adv Neurol"},{"key":"4508_CR22","doi-asserted-by":"crossref","unstructured":"Gerlach M, Double KL, Youdim MB, Riederer P (2006) Potential sources of increased iron in the substantia Nigra of parkinsonian patients. J Neural Transm Suppl 133\u2013142","DOI":"10.1007\/978-3-211-45295-0_21"},{"key":"4508_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.freeradbiomed.2013.01.017","volume":"62","author":"O Weinreb","year":"2013","unstructured":"Weinreb O, Mandel S, Youdim MB, Amit T (2013) Targeting dysregulation of brain iron homeostasis in parkinson\u2019s disease by iron chelators. Free Radic Biol Med 62:52\u201364","journal-title":"Free Radic Biol Med"},{"issue":"Pt 4","key":"4508_CR24","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/brain\/114.4.1953","volume":"114","author":"DT Dexter","year":"1991","unstructured":"Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson\u2019s disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114(Pt 4):1953\u20131975","journal-title":"Brain"},{"key":"4508_CR25","doi-asserted-by":"crossref","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B, Stockwell BR (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149:1060\u20131072","DOI":"10.1016\/j.cell.2012.03.042"},{"key":"4508_CR26","first-page":"273","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascon S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, Murphy ME, Overholtzer M, Oyagi A, Pagnussat GC, Park J, Ran Q, Rosenfeld CS, Salnikow K, Tang D, Torti FM, Torti SV, Toyokuni S, Woerpel KA, Zhang DD (2017) Ferroptosis: a regulated cell death nexus linking metabolism. Redox Biol Dis Cell 171:273\u2013285","journal-title":"Redox Biol Dis Cell"},{"key":"4508_CR27","doi-asserted-by":"publisher","first-page":"e1800311","DOI":"10.1002\/pmic.201800311","volume":"19","author":"GC Forcina","year":"2019","unstructured":"Forcina GC, Dixon SJ (2019) GPX4 at the crossroads of lipid homeostasis and ferroptosis. Proteomics 19:e1800311 PMID 30888116","journal-title":"Proteomics"},{"key":"4508_CR28","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/mds.26218","volume":"30","author":"N Pyatigorskaya","year":"2015","unstructured":"Pyatigorskaya N, Sharman M, Corvol JC, Valabregue R, Yahia-Cherif L, Poupon F, Cormier-Dequaire F, Siebner H, Klebe S, Vidailhet M, Brice A, Lehericy S (2015) High nigral iron deposition in LRRK2 and parkin mutation carriers using R2* relaxometry. Mov Disord 30:1077\u20131084 PMID 26011561","journal-title":"Mov Disord"},{"key":"4508_CR29","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0140-6736(87)91361-4","volume":"2","author":"DT Dexter","year":"1987","unstructured":"Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1987) Increased nigral iron content in postmortem parkinsonian brain. Lancet 2:1219\u20131220 PMID 2890848","journal-title":"Lancet"},{"key":"4508_CR30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/BF01291884","volume":"104","author":"RK Pearce","year":"1997","unstructured":"Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD (1997) Alterations in the distribution of glutathione in the substantia Nigra in parkinson\u2019s disease. J Neural Transm (Vienna) 104:661\u2013677 PMID 9444566","journal-title":"J Neural Transm (Vienna)"},{"key":"4508_CR31","doi-asserted-by":"publisher","first-page":"101890","DOI":"10.1016\/j.pneurobio.2020.101890","volume":"196","author":"L Mahoney-Sanchez","year":"2021","unstructured":"Mahoney-Sanchez L, Bouchaoui H, Ayton S, Devos D, Duce JA, Devedjian JC (2021) Ferroptosis and its potential role in the physiopathology of parkinson\u2019s disease. Prog Neurobiol 196:101890 PMID 32726602","journal-title":"Prog Neurobiol"},{"key":"4508_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1021\/acschemneuro.5b00253","volume":"7","author":"DI Finkelstein","year":"2016","unstructured":"Finkelstein DI, Hare DJ, Billings JL, Sedjahtera A, Nurjono M, Arthofer E, George S, Culvenor JG, Bush AI, Adlard PA (2016) Clioquinol improves cognitive, motor function, and microanatomy of the Alpha-Synuclein hA53T Transgenic mice. ACS Chem Neurosci 7:119\u2013129 PMID 26481462","journal-title":"ACS Chem Neurosci"},{"key":"4508_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.neuropharm.2017.05.019","volume":"123","author":"B Das","year":"2017","unstructured":"Das B, Rajagopalan S, Joshi GS, Xu L, Luo D, Andersen JK, Todi SV, Dutta AK (2017) A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses alpha-syn- and MPTP-induced toxicities in vivo. Neuropharmacology 123:88\u201399 PMID 28533164","journal-title":"Neuropharmacology"},{"key":"4508_CR34","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.freeradbiomed.2016.06.025","volume":"97","author":"S Baksi","year":"2016","unstructured":"Baksi S, Tripathi AK, Singh N (2016) Alpha-synuclein modulates retinal iron homeostasis by facilitating the uptake of transferrin-bound iron: implications for visual manifestations of parkinson\u2019s disease. Free Radic Biol Med 97:292\u2013306 PMID 27343690","journal-title":"Free Radic Biol Med"},{"key":"4508_CR35","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.redox.2017.08.015","volume":"14","author":"S Masaldan","year":"2018","unstructured":"Masaldan S, Clatworthy SAS, Gamell C, Meggyesy PM, Rigopoulos AT, Haupt S, Haupt Y, Denoyer D, Adlard PA, Bush AI, Cater MA (2018) Iron accumulation in senescent cells is coupled with impaired ferritinophagy and Inhibition of ferroptosis. Redox Biol 14:100\u2013115 PMID 28888202","journal-title":"Redox Biol"},{"key":"4508_CR36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1471-4159.1989.tb09150.x","volume":"52","author":"P Riederer","year":"1989","unstructured":"Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52:515\u2013520 PMID 2911028","journal-title":"J Neurochem"},{"key":"4508_CR37","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.spen.2006.08.002","volume":"13","author":"TA Rouault","year":"2006","unstructured":"Rouault TA, Cooperman S (2006) Brain iron metabolism. Semin Pediatr Neurol 13:142\u2013148 PMID 17101452","journal-title":"Semin Pediatr Neurol"},{"key":"4508_CR38","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1016\/j.bmc.2004.06.019","volume":"12","author":"AK Dutta","year":"2004","unstructured":"Dutta AK, Venkataraman SK, Fei XS, Kolhatkar R, Zhang S, Reith ME (2004) Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthale n-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors. Bioorg Med Chem 12:4361\u20134373 PMID 15265488","journal-title":"Bioorg Med Chem"},{"key":"4508_CR39","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1021\/acschemneuro.6b00356","volume":"8","author":"B Das","year":"2017","unstructured":"Das B, Kandegedara A, Xu L, Antonio T, Stemmler T, Reith ME, Dutta AK (2017) A novel Iron(II) preferring dopamine agonist chelator as potential symptomatic and neuroprotective therapeutic agent for parkinson\u2019s disease. ACS Chem Neurosci 8:723\u2013730 PMID 28106982","journal-title":"ACS Chem Neurosci"},{"key":"4508_CR40","doi-asserted-by":"publisher","first-page":"24301","DOI":"10.1074\/jbc.M010806200","volume":"276","author":"AM Romeo","year":"2001","unstructured":"Romeo AM, Christen L, Niles EG, Kosman DJ (2001) Intracellular chelation of iron by bipyridyl inhibits DNA virus replication: ribonucleotide reductase maturation as a probe of intracellular iron pools. J Biol Chem 276:24301\u201324308 PMID 11301321","journal-title":"J Biol Chem"},{"key":"4508_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1039\/TF9504600055","volume":"46","author":"JG Baxendale","year":"1950","unstructured":"Baxendale JG (1950) Equilibria in solutions of ferrous ions and ad-dipyridyl Trans Faraday SOC 46:55","journal-title":"Trans Faraday SOC"},{"key":"4508_CR42","doi-asserted-by":"publisher","first-page":"24209","DOI":"10.1074\/jbc.270.41.24209","volume":"270","author":"W Breuer","year":"1995","unstructured":"Breuer W, Epsztejn S, Cabantchik ZI (1995) Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II). J Biol Chem 270:24209\u201324215 PMID 7592626","journal-title":"J Biol Chem"},{"key":"4508_CR43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1006\/abio.1996.0032","volume":"233","author":"ZI Cabantchik","year":"1996","unstructured":"Cabantchik ZI, Glickstein H, Milgram P, Breuer W (1996) A fluorescence assay for assessing chelation of intracellular iron in a membrane model system and in mammalian cells. Anal Biochem 233:221\u2013227 PMID 8789722","journal-title":"Anal Biochem"},{"key":"4508_CR44","doi-asserted-by":"crossref","unstructured":"Das B, Kandegedara A, Xu L, Antonio T, Stemmler TL, Reith ME, Dutta AK (2017) A Novel Iron (II) preferring dopamine agonist chelator as potential symptomatic and neuroprotective therapeutic agent for Parkinson\u2019s Disease. ACS Chem Neurosci","DOI":"10.1021\/acschemneuro.6b00356"},{"key":"4508_CR45","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1038\/nprot.2006.378","volume":"1","author":"I Rahman","year":"2006","unstructured":"Rahman I, Kode A, Biswas SK (2006) Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc 1:3159\u20133165 PMID 17406579","journal-title":"Nat Protoc"},{"key":"4508_CR46","doi-asserted-by":"publisher","first-page":"9179","DOI":"10.1021\/acs.jmedchem.5b01031","volume":"58","author":"B Das","year":"2015","unstructured":"Das B, Vedachalam S, Luo D, Antonio T, Reith ME, Dutta AK (2015) Development of a highly potent D2\/D3 agonist and a partial agonist from Structure-Activity relationship study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydroben zo[d]thiazole-2,6-diamine analogues: implication in the treatment of parkinson\u2019s disease. J Med Chem 58:9179\u20139195 PMID 26555041","journal-title":"J Med Chem"},{"key":"4508_CR47","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0022-3565(25)28637-2","volume":"174","author":"GR Breese","year":"1970","unstructured":"Breese GR, Traylor TD (1970) Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons. J Pharmacol Exp Ther 174:413\u2013420 PMID 5456173","journal-title":"J Pharmacol Exp Ther"},{"key":"4508_CR48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/jnc.12767","volume":"131","author":"M Shah","year":"2014","unstructured":"Shah M, Rajagopalan S, Xu L, Voshavar C, Shurubor Y, Beal F, Andersen JK, Dutta AK (2014) The high-affinity D2\/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of parkinson\u2019s disease. J Neurochem 131:74\u201385 PMID 24848702","journal-title":"J Neurochem"},{"key":"4508_CR49","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.freeradbiomed.2018.09.014","volume":"133","author":"TM Seibt","year":"2019","unstructured":"Seibt TM, Proneth B, Conrad M (2019) Role of GPX4 in ferroptosis and its Pharmacological implication. Free Radic Biol Med 133:144\u2013152 PMID 30219704","journal-title":"Free Radic Biol Med"},{"key":"4508_CR50","doi-asserted-by":"crossref","unstructured":"Zhang W, Li X, Xu J, Wang Y, Xing Z, Hu S, Fan Q, Lu S, Cheng J, Gu J, Cai R (2022) The RSL3 induction of KLK lung adenocarcinoma cell ferroptosis by Inhibition of USP11 activity and the NRF2-GSH axis. Cancers (Basel) 14","DOI":"10.3390\/cancers14215233"},{"key":"4508_CR51","doi-asserted-by":"crossref","unstructured":"Crowley LC, Christensen ME, Waterhouse NJ (2016) Measuring mitochondrial transmembrane potential by TMRE staining. Cold Spring Harb Protoc 2016","DOI":"10.1101\/pdb.prot087361"},{"key":"4508_CR52","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/cdd.2015.158","volume":"23","author":"Y Xie","year":"2016","unstructured":"Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R, Tang D (2016) Ferroptosis: process and function. Cell Death Differ 23:369\u2013379","journal-title":"Cell Death Differ"},{"key":"4508_CR53","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","volume":"164","author":"S Duty","year":"2011","unstructured":"Duty S, Jenner P (2011) Animal models of parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164:1357\u20131391","journal-title":"Br J Pharmacol"},{"key":"4508_CR54","doi-asserted-by":"crossref","unstructured":"Ward RJ, Dexter DT, Crichton RR (2022) Iron, neuroinflammation and neurodegeneration. Int J Mol Sci 23","DOI":"10.3390\/ijms23137267"},{"key":"4508_CR55","doi-asserted-by":"crossref","unstructured":"Di Paola A, Tortora C, Argenziano M, Marrapodi MM, Rossi F (2022) Emerging roles of the iron chelators in inflammation. Int J Mol Sci 23","DOI":"10.3390\/ijms23147977"},{"key":"4508_CR56","doi-asserted-by":"crossref","unstructured":"Zille M, Kumar A, Kundu N, Bourassa MW, Wong VSC, Willis D, Karuppagounder SS, Ratan RR (2019) Ferroptosis in neurons and cancer cells is similar but differentially regulated by histone deacetylase inhibitors. eNeuro 6","DOI":"10.1523\/ENEURO.0263-18.2019"},{"key":"4508_CR57","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ana.410360305","volume":"36","author":"J Sian","year":"1994","unstructured":"Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in parkinson\u2019s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348\u2013355","journal-title":"Ann Neurol"},{"key":"4508_CR58","doi-asserted-by":"publisher","first-page":"e631","DOI":"10.1002\/cpz1.631","volume":"3","author":"J Baig","year":"2023","unstructured":"Baig J, Pradeepkiran JA, Reddy PH (2023) Methods to study mitochondria: techniques used to study the effects of age-related diseases including Alzheimer\u2019s. Curr Protoc 3:e631","journal-title":"Curr Protoc"},{"key":"4508_CR59","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.redox.2017.01.021","volume":"12","author":"WS Hambright","year":"2017","unstructured":"Hambright WS, Fonseca RS, Chen L, Na R, Ran Q (2017) Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol 12:8\u201317","journal-title":"Redox Biol"},{"key":"4508_CR60","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41556-020-0461-8","volume":"22","author":"H Lee","year":"2020","unstructured":"Lee H, Zandkarimi F, Zhang Y, Meena JK, Kim J, Zhuang L, Tyagi S, Ma L, Westbrook TF, Steinberg GR, Nakada D, Stockwell BR, Gan B (2020) Energy-stress-mediated AMPK activation inhibits ferroptosis. Nat Cell Biol 22:225\u2013234","journal-title":"Nat Cell Biol"},{"key":"4508_CR61","doi-asserted-by":"publisher","first-page":"101107","DOI":"10.1016\/j.redox.2019.101107","volume":"23","author":"M Dodson","year":"2019","unstructured":"Dodson M, Castro-Portuguez R, Zhang DD (2019) NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol 23:101107","journal-title":"Redox Biol"},{"key":"4508_CR62","doi-asserted-by":"publisher","first-page":"12943","DOI":"10.18632\/aging.103378","volume":"12","author":"H Dong","year":"2020","unstructured":"Dong H, Qiang Z, Chai D, Peng J, Xia Y, Hu R, Jiang H (2020) Nrf2 inhibits ferroptosis and protects against acute lung injury due to intestinal ischemia reperfusion via regulating SLC7A11 and HO-1. Aging 12:12943\u201312959","journal-title":"Aging"},{"key":"4508_CR63","doi-asserted-by":"crossref","unstructured":"Rochette L, Dogon G, Rigal E, Zeller M, Cottin Y, Vergely C (2022) Lipid peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis. Int J Mol Sci 24","DOI":"10.3390\/ijms24010449"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-025-04508-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-025-04508-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-025-04508-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T03:06:08Z","timestamp":1757387168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-025-04508-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["4508"],"URL":"https:\/\/doi.org\/10.1007\/s11064-025-04508-6","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"type":"print","value":"0364-3190"},{"type":"electronic","value":"1573-6903"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"264"}}